MDGN 205

Drug Profile

MDGN 205

Alternative Names: Glucagon-like peptide-2 gene therapy - Medgenics; MDGN-205; TARGTGLP-2

Latest Information Update: 30 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medgenics
  • Developer Aevi Genomic Medicine
  • Class Gene therapies; Peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Short bowel syndrome

Most Recent Events

  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
  • 06 Jan 2016 Medgenics in-licenses GeneRide promoter-less gene therapy technology from Stanford University
  • 26 Nov 2014 Preclinical trials in Short bowel syndrome in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top